← 產業報告目錄

Humanized Mouse and Rat Model Market by Type (Genetic Models, Cell-based Models, Rat Models), Application (Oncology, Immunology, Neuroscience, Toxicology, Infectious Diseases), End User (Pharma, Biotech), and Region - Global Forecast to 2030

出版商 MarketsandMarkets產業別 Healthcare & Life Sciences出版日期 2025-04-22頁數 255報告編號 BT4938

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The global humanized mouse and rat model market is anticipated to reach USD 409.8 million in 2030 from USD 276.2 million in 2025, with a significant CAGR of 8.2%. The market is growing strongly at a high CAGR due to rising R&D investments of pharmaceutical and biopharmaceutical firms. As the pipeline of R&D expands, the requirement for outsourcing analytical testing is set to rise, in addition to the research initiatives on rare diseases and orphan drugs. Furthermore, the high costs of in-house drug development have also contributed to this trend. Industry players will likely witness healthy growth opportunities due to technological advancements, new drug discovery techniques, patent expirations, and rising demand for specialized testing services among end users. “Humanized mouse model segment dominated the type segment in 2024” Based on type, the humanized mouse and rat model market has been segmented into humanized mouse models and humanized rat models. In 2024, humanized mouse models will have garnered the highest share in terms of revenue in the market. This segment is also expected to grow with the fastest CAGR through the forecast period. An increase in demand for cell-based humanized mouse models has contributed to the segment’s growth. These models are utilized in various applications, including the analysis of the safety and effectiveness of potential new drugs and in long-term studies in immuno-oncology, infectious diseases, and graft-versus-host disease. “The immunology & infectious diseases segment accounted for the second largest share of the market in 2024” The humanized mouse and rat model market is segmented based on application into oncology, immunology & infectious diseases, neuroscience, hematopoiesis, toxicology, and other applications. The immunology & infectious diseases segment is the second largest segment in the market in terms of revenue. Mouse models are used in immunology and inflammation studies as they help assess the physiological relevance of an experimental finding. Mouse models allow suitable alterations in the mouse genome at random or in specific regions, enabling a detailed study of immunological processes. “Pharmaceutical & Biotechnology Companies will likely record the highest CAGR during the forecast period” Based on the end users, the market is segmented into pharmaceutical & biotechnology companies, CROs & CDMOs, and academic & research institutes. Pharmaceutical & biotechnology companies dominated the segment in 2024. The largest share of pharmaceutical and biotechnology companies in the humanized mouse and rat model market is due to the rising expenditure for innovative drug development and the growing preference for personalized medicine. However, the CROs & CDMOs segment is expected to register the highest growth during the forecast period due to the increasing number of pharmaceutical & biotechnology companies outsourcing preclinical studies and research activities for drug development to this end user segment. “US to record the highest CAGR during the forecast period” The market is segmented by region into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America dominated the humanized mouse and rat model market in 2024 and is estimated to continue dominating during the forecast period. The US leads the North American market, driven by the presence of key players. The large share of the market is primarily driven by the rising funding for life sciences research and growing research on mAbs and biosimilars. The growing incidence of cancer is also expected to support market growth. In-depth interviews were conducted with chief executive officers (CEOs), directors, and other executives from various key organizations operating in the humanized mouse and rat model market. The primary interviews conducted for this report can be categorized as follows: • By Company Type: Tier 1 – 55%, Tier 2 – 25%, and Tier 3 – 20% • By Designation: C-level Executives – 45%, Directors – 30%, and Others – 25% • By Region: North America – 45%, Europe – 30%, Asia Pacific – 20%, Latin America – 3% and Middle East & Africa – 2% Charles River Laboratories (US), The Jackson Laboratory (JAX) (US), Taconic Biosciences, Inc. (US), JSR Corporation (US) (Crown Biosciences), Champions Oncology, Inc. (US), CLEA Japan Inc. (Japan), genOway (France), Inotiv (US), Janvier Labs (France), Altogen Labs (US), Vitalstar Biotechnology (China), Ingenious Targeting Laboratory (US), Reaction Biology (US), Harbour BioMed (Netherlands), Oncodesign Services (France), Pharmatest Services (Finland), Ozgene Pty Ltd. (Australia), TransCure bioServices (France), Cyagen Biosciences (US), Aragen Life Sciences Ltd. (India), GemPharmatech (China), and Biocytogen (US) are some of the key players in the humanized mouse and rat model market. Research Coverage: Humanized mouse and rat model market report is segmented based on type {[(humanized mouse models {genetic humanized mouse models and cell-based humanized mouse models (CD34 humanized mouse models, PBMC humanized mouse models, and BLT humanized mouse models)]} and humanized rat models), application (oncology, immunology and infectious diseases, neuroscience, hematopoiesis, toxicology, and other applications, end user (pharmaceutical & biotechnology companies, CROs & CDMOs, and academic & research institutes), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East, Africa). The report’s scope covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the humanized mouse and rat model market. A comprehensive analysis of the key players in the industry has been conducted to offer insights into their business overviews, products, key strategies, collaborations, partnerships, and agreements. This includes information about recent product launches, collaborations, acquisitions, and humanized mouse and rat model market developments. Key Benefits of Buying the Report: The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the humanized mouse and rat model and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges. The report provides insights on the following pointers: • Analysis of key drivers (rising use of humanized models in drug discovery research, emerging preclinical applications of humanized mouse models, government-funded initiatives for cancer research, and increasing R&D activities in the pharmaceutical & biotechnology industry), restraints (introduction of FDA Modernization Act 2.0/3.0, stringent regulatory compliance for ethical use of animal models), opportunities (growing preference for humanized PDX models, emergence of CRISPR in biomedical research), and challenges (alternatives for animal testing, limitations of humanized mouse models) influencing market growth. • Product Development/Innovation: Detailed insights on upcoming technologies in humanized mouse and rat models, research and development activities, and new product launches in the humanized mouse and rat model market. • Market Development: Comprehensive information about lucrative markets—the report analyses the market across varied regions. • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the humanized mouse and rat model market. • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players such as Charles River Laboratories (US), The Jackson Laboratory (JAX) (US), Inotiv (US), and genOway (France).
目錄 Table of Contents
1 INTRODUCTION 27 1.1 STUDY OBJECTIVES 27 1.2 MARKET DEFINITION 27 1.3 INCLUSIONS AND EXCLUSIONS 28 1.4 STUDY SCOPE 29 1.4.1 MARKET SEGMENTATION AND REGIONS COVERED 29 1.4.2 YEARS CONSIDERED 30 1.4.3 CURRENCY CONSIDERED 30 1.5 STAKEHOLDERS 30 1.6 SUMMARY OF CHANGES 31 2 RESEARCH METHODOLOGY 32 2.1 RESEARCH DATA 32 2.1.1 SECONDARY DATA 33 2.1.1.1 Objectives of secondary research 33 2.1.2 PRIMARY DATA 34 2.1.2.1 Objectives of primary research 34 2.2 MARKET SIZE ESTIMATION 35 2.2.1 GLOBAL MARKET ESTIMATION 35 2.2.2 SEGMENTAL MARKET ESTIMATION 38 2.3 GROWTH RATE PROJECTIONS 39 2.4 DATA TRIANGULATION 41 2.5 RESEARCH ASSUMPTIONS 42 2.6 RESEARCH LIMITATIONS 43 2.7 RISK ANALYSIS 43 3 EXECUTIVE SUMMARY 44 4 PREMIUM INSIGHTS 47 4.1 HUMANIZED MOUSE AND RAT MODEL MARKET OVERVIEW 47 4.2 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER AND COUNTRY, 2024 48 4.3 HUMANIZED MOUSE AND RAT MODEL MARKET, BY KEY COUNTRY 49 4.4 HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER 49 5 MARKET OVERVIEW 50 5.1 INTRODUCTION 50 5.2 MARKET DYNAMICS 50 5.2.1 DRIVERS 51 5.2.1.1 Rising use of humanized models in drug discovery research 51 5.2.1.2 Emerging preclinical applications of humanized mouse models 53 5.2.1.3 Government-funded initiatives for cancer research 53 5.2.1.4 Increasing R&D activities in pharmaceutical & biotechnology industry 54 5.2.2 RESTRAINTS 55 5.2.2.1 Introduction of FDA Modernization Act 2.0/3.0 55 5.2.2.2 Stringent regulatory compliance for ethical use of animal models 55 5.2.3 OPPORTUNITIES 56 5.2.3.1 Growing preference for humanized PDX models 56 5.2.3.2 Emergence of CRISPR in biomedical research 56 5.2.4 CHALLENGES 57 5.2.4.1 Alternative methods for animal testing 57 5.2.4.2 Limitations of humanized mouse models 57 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 58 5.4 PRICING ANALYSIS 59 5.4.1 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2022–2024 59 5.4.2 AVERAGE SELLING PRICE TREND OF KEY PRODUCTS, BY REGION 60 5.5 SUPPLY CHAIN ANALYSIS 62 5.6 VALUE CHAIN ANALYSIS 63 5.7 ECOSYSTEM ANALYSIS 65 5.8 INVESTMENT AND FUNDING SCENARIO 67 5.9 TECHNOLOGY ANALYSIS 68 5.9.1 KEY TECHNOLOGIES 68 5.9.1.1 CRISPR-Cas9 68 5.9.1.2 Tissue engineering 68 5.9.1.3 In vivo imaging 69 5.9.2 COMPLEMENTARY TECHNOLOGIES 69 5.9.2.1 3D cell culture 69 5.9.2.2 Organs-on-Chips 69 5.9.2.3 Biomarker discovery 69 5.9.3 ADJACENT TECHNOLOGIES 70 5.9.3.1 Proteomics 70 5.9.3.2 Microfluidics 70 5.9.3.3 Regenerative medicine 70 5.10 PATENT ANALYSIS 70 5.11 TRADE ANALYSIS 74 5.12 KEY CONFERENCES AND EVENTS, 2025–2026 76 5.13 REGULATORY LANDSCAPE 76 5.13.1 REGULATORY FRAMEWORK 76 5.13.2 NORTH AMERICA 76 5.13.3 EUROPE 77 5.13.4 ASIA PACIFIC 79 5.13.4.1 China 79 5.13.4.2 Japan 79 5.13.4.3 India 80 5.13.4.4 Australia 80 5.13.5 LATIN AMERICA 81 5.13.6 MIDDLE EAST & AFRICA 81 5.13.7 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 81 5.14 PORTER’S FIVE FORCES ANALYSIS 83 5.14.1 THREAT OF NEW ENTRANTS 84 5.14.2 THREAT OF SUBSTITUTES 84 5.14.3 BARGAINING POWER OF SUPPLIERS 85 5.14.4 BARGAINING POWER OF BUYERS 85 5.14.5 INTENSITY OF COMPETITIVE RIVALRY 85 5.15 KEY STAKEHOLDERS AND BUYING CRITERIA 85 5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS 85 5.15.2 KEY BUYING CRITERIA, BY END USER 86 5.16 IMPACT OF AI ON HUMANIZED MOUSE AND RAT MODEL MARKET 87 5.16.1 INTRODUCTION 87 5.16.2 MARKET POTENTIAL OF AI IN HUMANIZED MOUSE AND RAT MODELS 87 5.16.3 AI USE CASES 88 5.16.4 KEY COMPANIES IMPLEMENTING AI 88 5.16.5 FUTURE OF GENERATIVE AI IN HUMANIZED MOUSE AND RAT MODEL MARKET 88 6 HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE 89 6.1 INTRODUCTION 90 6.2 HUMANIZED MOUSE MODELS 91 6.2.1 GENETIC HUMANIZED MOUSE MODELS 94 6.2.1.1 Advancements in genetical engineering technologies to drive market 94 6.2.2 CELL-BASED HUMANIZED MOUSE MODELS 96 6.2.2.1 CD34 humanized mouse models 98 6.2.2.1.1 Rising demand for stem cell therapy to propel market 98 6.2.2.2 PBMC humanized mouse models 100 6.2.2.2.1 Growing prevalence of infectious diseases to boost demand 100 6.2.2.3 BLT humanized mouse models 103 6.2.2.3.1 Surge in HIV cases to drive market 103 6.3 HUMANIZED RAT MODELS 105 6.3.1 PREFERENCE FOR SRG RAT MODELS FOR RESEARCH STUDIES WITH LARGE SAMPLE SIZE SUPPORTS THE SEGMENT GROWTH 105   7 HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER 107 7.1 INTRODUCTION 108 7.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 108 7.2.1 GROWING ADOPTION OF HU-MICE MODELS IN VACCINE DEVELOPMENT TO BOOST SEGMENT GROWTH 108 7.3 CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT DEVELOPMENT MANUFACTURING ORGANIZATIONS 111 7.3.1 OUTSOURCING OF DRUG DISCOVERY SERVICES BY PHARMA & BIOTECH COMPANIES TO PROPEL MARKET 111 7.4 ACADEMIC & RESEARCH INSTITUTES 113 7.4.1 SUPPORTIVE FUNDING INVESTMENTS FOR LIFE SCIENCE RESEARCH TO DRIVE MARKET 113 8 HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION 116 8.1 INTRODUCTION 117 8.2 ONCOLOGY 117 8.2.1 UTILIZATION OF MOUSE MODELS IN CANCER RESEARCH TO DRIVE MARKET 117 8.3 IMMUNOLOGY AND INFECTIOUS DISEASES 120 8.3.1 DEVELOPMENT OF ADVANCED MODELS FOR TREATMENT OF RARE DISEASES TO DRIVE MARKET 120 8.4 NEUROSCIENCE 122 8.4.1 RISING INCIDENCE OF CNS DISORDERS TO DRIVE MARKET 122 8.5 TOXICOLOGY 124 8.5.1 INCREASING CLINICAL TRIALS FOR TOXICOLOGY STUDIES TO SUPPORT MARKET GROWTH 124 8.6 HEMATOPOIESIS 126 8.6.1 RISING DEMAND FOR STEM CELL THERAPY TO DRIVE MARKET 126 8.7 OTHER APPLICATIONS 128 9 HUMANIZED MOUSE AND RAT MODEL MARKET, BY REGION 131 9.1 INTRODUCTION 132 9.2 NORTH AMERICA 133 9.2.1 MACROECONOMIC OUTLOOK OF NORTH AMERICA 136 9.2.2 US 136 9.2.2.1 Growing research initiatives on mAbs and biosimilars to drive market 136 9.2.3 CANADA 139 9.2.3.1 Government initiatives on stem cell research to drive market 139 9.3 EUROPE 141 9.3.1 MACROECONOMIC OUTLOOK OF EUROPE 143 9.3.2 GERMANY 145 9.3.2.1 Rising pharmaceutical R&D expenditure to drive market 145 9.3.3 UK 147 9.3.3.1 Growing investments in cancer research to drive market 147 9.3.4 FRANCE 149 9.3.4.1 Rising initiatives for genomics research to support market growth 149 9.3.5 ITALY 151 9.3.5.1 Robust pharmaceutical production to fuel market 151 9.3.6 SPAIN 153 9.3.6.1 Rising growth in biotech industry to drive market 153 9.3.7 REST OF EUROPE 155 9.4 ASIA PACIFIC 157 9.4.1 MACROECONOMIC OUTLOOK OF ASIA PACIFIC 161 9.4.2 CHINA 161 9.4.2.1 High growth in pharmaceutical industry to drive market 161 9.4.3 JAPAN 164 9.4.3.1 Growing research collaborations among pharmaceutical companies to drive market 164 9.4.4 INDIA 166 9.4.4.1 Growth in biotech industry to drive market 166 9.4.5 SOUTH KOREA 169 9.4.5.1 Rising government-funded investments for pharmaceutical R&D to drive market 169 9.4.6 AUSTRALIA 171 9.4.6.1 Rising biomedical research projects to drive market 171 9.4.7 REST OF ASIA PACIFIC 173 9.5 LATIN AMERICA 175 9.5.1 GROWING PRESENCE OF PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO PROPEL MARKET 175 9.5.2 MACROECONOMIC OUTLOOK OF LATIN AMERICA 177 9.6 MIDDLE EAST 178 9.6.1 GROWING PHARMACEUTICAL MARKET IN COUNTRIES TO SUPPORT MARKET GROWTH 178 9.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 180 9.7 AFRICA 181 9.7.1 GROWING PHARMACEUTICAL INDUSTRY TO SUPPORT MARKET GROWTH 181 9.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 183 10 COMPETITIVE LANDSCAPE 184 10.1 INTRODUCTION 184 10.2 KEY PLAYER STRATEGY/RIGHT TO WIN 184 10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN HUMANIZED MOUSE AND RAT MODEL MARKET 185 10.3 REVENUE ANALYSIS, 2020−2024 187 10.4 MARKET SHARE ANALYSIS, 2024 187 10.4.1 HUMANIZED MOUSE AND RAT MODEL MARKET 188 10.5 COMPANY VALUATION AND FINANCIAL METRICS 190 10.5.1 FINANCIAL METRICS 190 10.6 BRAND/PRODUCT COMPARISON 191 10.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 192 10.7.1 STARS 192 10.7.2 EMERGING LEADERS 192 10.7.3 PERVASIVE PLAYERS 192 10.7.4 PARTICIPANTS 192 10.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 194 10.7.5.1 Company footprint 194 10.7.5.2 Region footprint 195 10.7.5.3 Type footprint 196 10.7.5.4 Application footprint 197 10.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 198 10.8.1 PROGRESSIVE COMPANIES 198 10.8.2 RESPONSIVE COMPANIES 198 10.8.3 DYNAMIC COMPANIES 198 10.8.4 STARTING BLOCKS 198 10.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES 200 10.8.5.1 Detailed list of key startups/SMEs 200 10.8.5.2 Competitive benchmarking of key startups/SMEs 201 10.9 COMPETITIVE SCENARIO 202 10.9.1 PRODUCT LAUNCHES & APPROVALS 202 10.9.2 DEALS 202 10.9.3 EXPANSIONS 204 11 COMPANY PROFILES 205 11.1 KEY PLAYERS 205 11.1.1 CHARLES RIVER LABORATORIES 205 11.1.1.1 Business overview 205 11.1.1.2 Products offered 206 11.1.1.3 Recent developments 207 11.1.1.3.1 Deals 207 11.1.1.3.2 Other developments 207 11.1.1.4 MnM view 208 11.1.1.4.1 Key strengths 208 11.1.1.4.2 Strategic choices 208 11.1.1.4.3 Weaknesses and competitive threats 208 11.1.2 THE JACKSON LABORATORY 209 11.1.2.1 Business overview 209 11.1.2.2 Products offered 211 11.1.2.3 Recent developments 212 11.1.2.3.1 Deals 212   11.1.2.4 MnM view 212 11.1.2.4.1 Key strengths 212 11.1.2.4.2 Strategic choices 212 11.1.2.4.3 Weaknesses and competitive threats 212 11.1.3 INOTIV 213 11.1.3.1 Business overview 213 11.1.3.2 Products offered 215 11.1.3.3 Recent developments 216 11.1.3.3.1 Deals 216 11.1.3.4 MnM view 217 11.1.3.4.1 Key strengths 217 11.1.3.4.2 Strategic choices 217 11.1.3.4.3 Weaknesses and competitive threats 217 11.1.4 GENOWAY 218 11.1.4.1 Business overview 218 11.1.4.2 Products offered 218 11.1.4.3 Recent developments 220 11.1.4.3.1 Other developments 220 11.1.4.4 MnM view 220 11.1.4.4.1 Key strengths 220 11.1.4.4.2 Strategic choices 220 11.1.4.4.3 Weaknesses and competitive threats 220 11.1.5 TACONIC BIOSCIENCES, INC. 221 11.1.5.1 Business overview 221 11.1.5.2 Products offered 222 11.1.5.3 Recent developments 223 11.1.5.3.1 Product launches 223 11.1.5.3.2 Expansions 223 11.1.6 JSR CORPORATION 224 11.1.6.1 Business overview 224 11.1.6.2 Products offered 225 11.1.6.3 Recent developments 226 11.1.6.3.1 Deals 226 11.1.6.3.2 Expansions 227 11.1.7 CHAMPIONS ONCOLOGY, INC. 228 11.1.7.1 Business overview 228 11.1.7.2 Products offered 229 11.1.8 JANVIER LABS 230 11.1.8.1 Business overview 230 11.1.8.2 Products offered 230 11.1.8.3 Recent developments 231 11.1.8.3.1 Deals 231 11.1.9 VITALSTAR BIOTECHNOLOGY 232 11.1.9.1 Business overview 232 11.1.9.2 Products offered 232 11.1.10 INGENIOUS TARGETING LABORATORY 233 11.1.10.1 Business overview 233 11.1.10.2 Products offered 234 11.1.11 HARBOUR BIOMED 235 11.1.11.1 Business overview 235 11.1.11.2 Products offered 236 11.1.11.3 Recent developments 236 11.1.11.3.1 Deals 236 11.1.12 ONCODESIGN SERVICES 237 11.1.12.1 Business overview 237 11.1.12.2 Products offered 237 11.1.13 PHARMATEST SERVICES 238 11.1.13.1 Business overview 238 11.1.13.2 Products offered 238 11.2 OTHER PLAYERS 239 11.2.1 OZGENE PTY LTD. 239 11.2.2 CLEA JAPAN, INC. 240 11.2.3 ALTOGEN LABS 241 11.2.4 REACTION BIOLOGY 242 11.2.5 TRANSCURE BIOSERVICES 243 11.2.6 CYAGEN 244 11.2.7 ARAGEN LIFE SCIENCES LTD. 245 11.2.8 BIOCYTOGEN 246 11.2.9 GEMPHARMATECH 247 12 APPENDIX 248 12.1 DISCUSSION GUIDE 248 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 251 12.3 CUSTOMIZATION OPTIONS 253 12.4 RELATED REPORTS 253 12.5 AUTHOR DETAILS 254
圖表清單 List of Tables & Figures
TABLE 1 HUMANIZED MOUSE AND RAT MODEL MARKET: INCLUSIONS AND EXCLUSIONS 28 TABLE 2 IMPACT ANALYSIS OF SUPPLY AND DEMAND-SIDE FACTORS 40 TABLE 3 HUMANIZED MOUSE AND RAT MODEL MARKET: RISK ANALYSIS 43 TABLE 4 HUMANIZED MOUSE AND RAT MODEL MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS 51 TABLE 5 NUMBER OF R&D PRODUCTS, BY INDICATION (2024) 54 TABLE 6 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2022–2024 (USD MILLION) 59 TABLE 7 AVERAGE SELLING PRICE TREND OF KEY PRODUCTS, BY REGION, 2022–2024 (USD) 60 TABLE 8 AVERAGE SELLING PRICE TREND OF KEY PRODUCTS (HUMANIZED MOUSE MODELS), BY REGION, 2022–2024 (USD) 61 TABLE 9 HUMANIZED MOUSE AND RAT MODEL MARKET: ROLE OF COMPANIES IN ECOSYSTEM 66 TABLE 10 INVESTMENT AND FUNDING ACTIVITY, BY KEY PLAYER, 2021−2025 67 TABLE 11 HUMANIZED MOUSE AND RAT MODEL MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2021–2024 72 TABLE 12 IMPORT DATA FOR LABORATORY MOUSE 74 TABLE 13 EXPORT DATA FOR LABORATORY MOUSE 75 TABLE 14 HUMANIZED MOUSE AND RAT MODEL MARKET: KEY CONFERENCES AND EVENTS, 2025–2026 76 TABLE 15 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 81 TABLE 16 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 82 TABLE 17 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 82 TABLE 18 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 83 TABLE 19 HUMANIZED MOUSE AND RAT MODEL MARKET: PORTER’S FIVE FORCES ANALYSIS 83 TABLE 20 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS (%) 86 TABLE 21 KEY BUYING CRITERIA, BY END USER 86 TABLE 22 HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION) 90 TABLE 23 HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023–2030 (THOUSAND UNITS) 90 TABLE 24 HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 92 TABLE 25 HUMANIZED MOUSE MODELS MARKET, BY REGION, 2023–2030 (USD MILLION) 93 TABLE 26 NORTH AMERICA: HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 93 TABLE 27 EUROPE: HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 93 TABLE 28 ASIA PACIFIC: HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 94   TABLE 29 GENETIC HUMANIZED MOUSE MODELS MARKET, BY REGION, 2023–2030 (USD MILLION) 95 TABLE 30 NORTH AMERICA: GENETIC HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 95 TABLE 31 EUROPE: GENETIC HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 95 TABLE 32 ASIA PACIFIC: GENETIC HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 96 TABLE 33 CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 96 TABLE 34 CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY REGION, 2023–2030 (USD MILLION) 97 TABLE 35 NORTH AMERICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 97 TABLE 36 EUROPE: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 97 TABLE 37 ASIA PACIFIC: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 98 TABLE 38 CD34 HUMANIZED MODELS MARKET, BY REGION, 2023–2030 (USD MILLION) 99 TABLE 39 NORTH AMERICA: CD34 HUMANIZED MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 99 TABLE 40 EUROPE: CD34 HUMANIZED MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 100 TABLE 41 ASIA PACIFIC: CD34 HUMANIZED MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 100 TABLE 42 PBMC HUMANIZED MICE MODELS MARKET, BY REGION, 2023–2030 (USD MILLION) 101 TABLE 43 NORTH AMERICA: PBMC HUMANIZED MICE MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 102 TABLE 44 EUROPE: PBMC HUMANIZED MICE MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 102 TABLE 45 ASIA PACIFIC: PBMC HUMANIZED MICE MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 102 TABLE 46 BLT HUMANIZED MOUSE MODELS MARKET, BY REGION, 2023–2030 (USD MILLION) 103 TABLE 47 NORTH AMERICA: BLT HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 104 TABLE 48 EUROPE: BLT HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 104 TABLE 49 ASIA PACIFIC: BLT HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 104 TABLE 50 HUMANIZED RAT MODELS MARKET, BY REGION, 2023–2030 (USD MILLION) 105 TABLE 51 NORTH AMERICA: HUMANIZED RAT MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 106 TABLE 52 EUROPE: HUMANIZED RAT MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 106 TABLE 53 ASIA PACIFIC: HUMANIZED RAT MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 106 TABLE 54 HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023–2030 (USD MILLION) 108   TABLE 55 USE OF HUMANIZED MICE MODELS IN DEVELOPED AND TESTED VACCINES 109 TABLE 56 HUMANIZED MOUSE AND RAT MODEL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 110 TABLE 57 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 110 TABLE 58 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 110 TABLE 59 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 111 TABLE 60 HUMANIZED MOUSE AND RAT MODEL MARKET FOR CROS AND CDMOS, BY REGION, 2023–2030 (USD MILLION) 112 TABLE 61 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR CROS AND CDMOS, BY COUNTRY, 2023–2030 (USD MILLION) 112 TABLE 62 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR CROS AND CDMOS, BY COUNTRY, 2023–2030 (USD MILLION) 112 TABLE 63 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR CROS AND CDMOS, BY COUNTRY, 2023–2030 (USD MILLION) 113 TABLE 64 HUMANIZED MOUSE AND RAT MODEL MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 114 TABLE 65 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 114 TABLE 66 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 115 TABLE 67 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 115 TABLE 68 HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 117 TABLE 69 HUMANIZED MOUSE AND RAT MODEL MARKET FOR ONCOLOGY, BY REGION, 2023–2030 (USD MILLION) 119 TABLE 70 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 119 TABLE 71 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 119 TABLE 72 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 120 TABLE 73 HUMANIZED MOUSE AND RAT MODEL MARKET FOR IMMUNOLOGY AND INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION) 121 TABLE 74 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR IMMUNOLOGY AND INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 121 TABLE 75 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR IMMUNOLOGY AND INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 121 TABLE 76 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR IMMUNOLOGY AND INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 122 TABLE 77 HUMANIZED MOUSE AND RAT MODEL MARKET FOR NEUROSCIENCE, BY REGION, 2023–2030 (USD MILLION) 123 TABLE 78 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR NEUROSCIENCE, BY COUNTRY, 2023–2030 (USD MILLION) 123   TABLE 79 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR NEUROSCIENCE, BY COUNTRY, 2023–2030 (USD MILLION) 123 TABLE 80 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR NEUROSCIENCE, BY COUNTRY, 2023–2030 (USD MILLION) 124 TABLE 81 HUMANIZED MOUSE AND RAT MODEL MARKET FOR TOXICOLOGY, BY REGION, 2023–2030 (USD MILLION) 125 TABLE 82 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR TOXICOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 125 TABLE 83 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR TOXICOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 125 TABLE 84 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR TOXICOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 126 TABLE 85 HUMANIZED MOUSE AND RAT MODEL MARKET FOR HEMATOPOIESIS, BY REGION, 2023–2030 (USD MILLION) 127 TABLE 86 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR HEMATOPOIESIS, BY COUNTRY, 2023–2030 (USD MILLION) 127 TABLE 87 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR HEMATOPOIESIS, BY COUNTRY, 2023–2030 (USD MILLION) 127 TABLE 88 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR HEMATOPOIESIS, BY COUNTRY, 2023–2030 (USD MILLION) 128 TABLE 89 HUMANIZED MOUSE AND RAT MODEL MARKET FOR OTHER APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 129 TABLE 90 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 129 TABLE 91 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 129 TABLE 92 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 130 TABLE 93 HUMANIZED MOUSE AND RAT MODEL MARKET, BY REGION, 2023–2030 (USD MILLION) 132 TABLE 94 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 134 TABLE 95 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION) 134 TABLE 96 NORTH AMERICA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 134 TABLE 97 NORTH AMERICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 135 TABLE 98 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 135 TABLE 99 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023–2030 (USD MILLION) 135 TABLE 100 KEY MACROECONOMIC INDICATORS OF NORTH AMERICA 136 TABLE 101 US: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION) 137 TABLE 102 US: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 137 TABLE 103 US: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 138   TABLE 104 US: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 138 TABLE 105 US: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023–2030 (USD MILLION) 138 TABLE 106 CANADA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION) 139 TABLE 107 CANADA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 140 TABLE 108 CANADA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 140 TABLE 109 CANADA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 140 TABLE 110 CANADA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023–2030 (USD MILLION) 141 TABLE 111 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 141 TABLE 112 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION) 142 TABLE 113 EUROPE: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 142 TABLE 114 EUROPE: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 142 TABLE 115 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 143 TABLE 116 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023–2030 (USD MILLION) 143 TABLE 117 KEY MACROECONOMIC INDICATORS OF EUROPE 144 TABLE 118 GERMANY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION) 145 TABLE 119 GERMANY: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 145 TABLE 120 GERMANY: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 146 TABLE 121 GERMANY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 146 TABLE 122 GERMANY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023–2030 (USD MILLION) 146 TABLE 123 UK: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION) 147 TABLE 124 UK: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 147 TABLE 125 UK: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 148 TABLE 126 UK: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 148 TABLE 127 UK: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023–2030 (USD MILLION) 148 TABLE 128 FRANCE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION) 149   TABLE 129 FRANCE: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 150 TABLE 130 FRANCE: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 150 TABLE 131 FRANCE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 150 TABLE 132 FRANCE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023–2030 (USD MILLION) 151 TABLE 133 ITALY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION) 152 TABLE 134 ITALY: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 152 TABLE 135 ITALY: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 152 TABLE 136 ITALY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 153 TABLE 137 ITALY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023–2030 (USD MILLION) 153 TABLE 138 SPAIN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION) 154 TABLE 139 SPAIN: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 154 TABLE 140 SPAIN: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 154 TABLE 141 SPAIN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 155 TABLE 142 SPAIN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023–2030 (USD MILLION) 155 TABLE 143 REST OF EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION) 156 TABLE 144 REST OF EUROPE: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 156 TABLE 145 REST OF EUROPE: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 156 TABLE 146 REST OF EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 157 TABLE 147 REST OF EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023–2030 (USD MILLION) 157 TABLE 148 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 159 TABLE 149 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION) 159 TABLE 150 ASIA PACIFIC: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 159 TABLE 151 ASIA PACIFIC: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 160 TABLE 152 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 160 TABLE 153 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023–2030 (USD MILLION) 160   TABLE 154 KEY MACROECONOMIC INDICATORS OF ASIA PACIFIC 161 TABLE 155 CHINA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION) 162 TABLE 156 CHINA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 163 TABLE 157 CHINA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 163 TABLE 158 CHINA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 163 TABLE 159 CHINA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023–2030 (USD MILLION) 164 TABLE 160 JAPAN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION) 165 TABLE 161 JAPAN: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 165 TABLE 162 JAPAN: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 165 TABLE 163 JAPAN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 166 TABLE 164 JAPAN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023–2030 (USD MILLION) 166 TABLE 165 INDIA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION) 167 TABLE 166 INDIA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 167 TABLE 167 INDIA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 168 TABLE 168 INDIA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 168 TABLE 169 INDIA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023–2030 (USD MILLION) 168 TABLE 170 SOUTH KOREA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION) 169 TABLE 171 SOUTH KOREA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 170 TABLE 172 SOUTH KOREA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 170 TABLE 173 SOUTH KOREA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 170 TABLE 174 SOUTH KOREA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023–2030 (USD MILLION) 171 TABLE 175 AUSTRALIA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION) 171 TABLE 176 AUSTRALIA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 172 TABLE 177 AUSTRALIA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 172 TABLE 178 AUSTRALIA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 172   TABLE 179 AUSTRALIA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023–2030 (USD MILLION) 173 TABLE 180 REST OF ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION) 173 TABLE 181 REST OF ASIA PACIFIC: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 173 TABLE 182 REST OF ASIA PACIFIC: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 174 TABLE 183 REST OF ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 174 TABLE 184 REST OF ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023–2030 (USD MILLION) 174 TABLE 185 LATIN AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION) 175 TABLE 186 LATIN AMERICA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 175 TABLE 187 LATIN AMERICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 176 TABLE 188 LATIN AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 176 TABLE 189 LATIN AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023–2030 (USD MILLION) 176 TABLE 190 KEY MACROECONOMIC INDICATORS OF LATIN AMERICA 177 TABLE 191 MIDDLE EAST: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION) 178 TABLE 192 MIDDLE EAST: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 178 TABLE 193 MIDDLE EAST: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 179 TABLE 194 MIDDLE EAST: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 179 TABLE 195 MIDDLE EAST: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023–2030 (USD MILLION) 179 TABLE 196 KEY MACROECONOMIC INDICATORS OF MIDDLE EAST 180 TABLE 197 AFRICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION) 181 TABLE 198 AFRICA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 181 TABLE 199 AFRICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 182 TABLE 200 AFRICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 182 TABLE 201 AFRICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023–2030 (USD MILLION) 182 TABLE 202 KEY MACROECONOMIC INDICATORS OF AFRICA 183 TABLE 203 STRATEGIES ADOPTED BY KEY PLAYERS IN HUMANIZED MOUSE AND RAT MODEL MARKET, 2021−2024 185   TABLE 204 HUMANIZED MOUSE AND RAT MODEL MARKET: DEGREE OF COMPETITION 188 TABLE 205 HUMANIZED MOUSE AND RAT MODEL MARKET: REGION FOOTPRINT 195 TABLE 206 HUMANIZED MOUSE AND RAT MODEL MARKET: TYPE FOOTPRINT 196 TABLE 207 HUMANIZED MOUSE AND RAT MODEL MARKET: APPLICATION FOOTPRINT 197 TABLE 208 HUMANIZED MOUSE AND RAT MODEL MARKET: KEY STARTUPS/SMES 200 TABLE 209 HUMANIZED MOUSE AND RAT MODEL MARKET: COMPETITIVE BENCHMARKING OF KEY START UPS/SMES 201 TABLE 210 HUMANIZED MOUSE AND RAT MODEL MARKET: PRODUCT LAUNCHES, JANUARY 2021–MARCH 2025 202 TABLE 211 HUMANIZED MOUSE AND RAT MODEL MARKET: DEALS, JANUARY 2021–MARCH 2025 203 TABLE 212 HUMANIZED MOUSE AND RAT MODEL MARKET: EXPANSIONS, JANUARY 2021–MARCH 2025 204 TABLE 213 CHARLES RIVER LABORATORIES: COMPANY OVERVIEW 205 TABLE 214 CHARLES RIVER LABORATORIES: PRODUCTS OFFERED 206 TABLE 215 CHARLES RIVER LABORATORIES: DEALS, JANUARY 2021–JANUARY 2025 207 TABLE 216 CHARLES RIVER LABORATORIES: OTHER DEVELOPMENTS, JANUARY 2021–JANUARY 2025 207 TABLE 217 THE JACKSON LABORATORY: COMPANY OVERVIEW 209 TABLE 218 THE JACKSON LABORATORY: PRODUCTS OFFERED 211 TABLE 219 THE JACKSON LABORATORY: DEALS, JANUARY 2021–JANUARY 2025 212 TABLE 220 INOTIV: COMPANY OVERVIEW 213 TABLE 221 INOTIV: PRODUCTS OFFERED 215 TABLE 222 INOTIV: DEALS, JANUARY 2021–JANUARY 2025 216 TABLE 223 GENOWAY: COMPANY OVERVIEW 218 TABLE 224 GENOWAY: PRODUCTS OFFERED 218 TABLE 225 GENOWAY: OTHER DEVELOPMENTS, JANUARY 2021–JANUARY 2025 220 TABLE 226 TACONIC BIOSCIENCES, INC.: COMPANY OVERVIEW 221 TABLE 227 TACONIC BIOSCIENCES, INC.: PRODUCTS OFFERED 222 TABLE 228 TACONIC BIOSCIENCES, INC.: PRODUCT LAUNCHES, JANUARY 2021–JANUARY 2025 223 TABLE 229 TACONIC BIOSCIENCES, INC.: EXPANSIONS, JANUARY 2021–JANUARY 2025 223 TABLE 230 JSR CORPORATION: COMPANY OVERVIEW 224 TABLE 231 JSR CORPORATION: PRODUCTS OFFERED 225 TABLE 232 JSR CORPORATION: DEALS, JANUARY 2021–JANUARY 2025 226 TABLE 233 JSR CORPORATION: EXPANSIONS, JANUARY 2021–JANUARY 2025 227 TABLE 234 CHAMPIONS ONCOLOGY, INC.: COMPANY OVERVIEW 228 TABLE 235 CHAMPIONS ONCOLOGY, INC.: PRODUCTS OFFERED 229 TABLE 236 JANVIER LABS: COMPANY OVERVIEW 230 TABLE 237 JANVIER LABS: PRODUCTS OFFERED 230 TABLE 238 JANVIER LABS: DEALS, JANUARY 2021–JANUARY 2025 231 TABLE 239 VITALSTAR BIOTECHNOLOGY: COMPANY OVERVIEW 232 TABLE 240 VITALSTAR BIOTECHNOLOGY: PRODUCTS OFFERED 232 TABLE 241 INGENIOUS TARGETING LABORATORY: COMPANY OVERVIEW 233 TABLE 242 INGENIOUS TARGETING LABORATORY: PRODUCTS OFFERED 234 TABLE 243 HARBOUR BIOMED: COMPANY OVERVIEW 235 TABLE 244 HARBOUR BIOMED: PRODUCTS OFFERED 236 TABLE 245 HARBOUR BIOMED: DEALS, JANUARY 2021–JANUARY 2025 236 TABLE 246 ONCODESIGN SERVICES: COMPANY OVERVIEW 237 TABLE 247 ONCODESIGN SERVICES: PRODUCTS OFFERED 237 TABLE 248 PHARMATEST SERVICES: COMPANY OVERVIEW 238 TABLE 249 PHARMATEST SERVICES: PRODUCTS OFFERED 238 TABLE 250 OZGENE PTY LTD.: COMPANY OVERVIEW 239 TABLE 251 CLEA JAPAN, INC.: COMPANY OVERVIEW 240 TABLE 252 ALTOGEN LABS: COMPANY OVERVIEW 241 TABLE 253 REACTION BIOLOGY: COMPANY OVERVIEW 242 TABLE 254 TRANSCURE BIOSERVICES: COMPANY OVERVIEW 243 TABLE 255 CYAGEN: COMPANY OVERVIEW 244 TABLE 256 ARAGEN LIFE SCIENCES LTD.: COMPANY OVERVIEW 245 TABLE 257 BIOCYTOGEN: COMPANY OVERVIEW 246 TABLE 258 GEMPHARMATECH: COMPANY OVERVIEW 247 _ FIGURE 1 HUMANIZED MOUSE AND RAT MODEL MARKET SEGMENTATION AND REGIONS CONSIDERED 29 FIGURE 2 HUMANIZED MOUSE AND RAT MODEL MARKET: YEARS CONSIDERED 30 FIGURE 3 HUMANIZED MOUSE AND RAT MODEL MARKET: RESEARCH DESIGN 32 FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY RESPONDENT, DESIGNATION, AND REGION 34 FIGURE 5 GLOBAL HUMANIZED MOUSE AND RAT MODEL MARKET SIZE ESTIMATION, 2024 35 FIGURE 6 COMPANY REVENUE ANALYSIS-BASED ESTIMATION, 2024 36 FIGURE 7 REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF CHARLES RIVER LABORATORIES, 2024 36 FIGURE 8 MARKET SIZE VALIDATION FROM PRIMARIES 38 FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 38 FIGURE 10 HUMANIZED MOUSE AND RAT MODEL MARKET: CAGR PROJECTIONS, 2025–2030 40 FIGURE 11 HUMANIZED MOUSE AND RAT MODEL MARKET: DATA TRIANGULATION 41 FIGURE 12 HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION) 44 FIGURE 13 HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION) 45 FIGURE 14 HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 45 FIGURE 15 REGIONAL SNAPSHOT OF HUMANIZED MOUSE AND RAT MODEL MARKET, 2025–2030 46 FIGURE 16 RISING USE OF HUMANIZED MODELS IN DRUG DISCOVERY RESEARCH TO DRIVE MARKET 47 FIGURE 17 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN US IN 2024 48 FIGURE 18 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 49 FIGURE 19 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT DOMINATED MARKET IN 2024 49 FIGURE 20 HUMANIZED MOUSE AND RAT MODEL MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 50 FIGURE 21 NUMBER OF CLINICAL TRIALS REGISTERED FOR CANCER IMMUNOTHERAPIES, 2020–2024 52 FIGURE 22 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 58 FIGURE 23 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2022–2024 (USD) 59 FIGURE 24 AVERAGE SELLING PRICE TREND OF KEY PRODUCTS, BY REGION, 2022–2024 (USD) 60 FIGURE 25 AVERAGE SELLING PRICE TREND OF KEY PRODUCTS, BY REGION, 2022–2024 (USD) 61 FIGURE 26 HUMANIZED MOUSE AND RAT MODEL MARKET: SUPPLY CHAIN ANALYSIS 63 FIGURE 27 HUMANIZED MOUSE AND RAT MODEL MARKET: VALUE CHAIN ANALYSIS 63 FIGURE 28 HUMANIZED MOUSE AND RAT MODEL MARKET ECOSYSTEM 66   FIGURE 29 INVESTMENT AND FUNDING SCENARIO, 2021–2025 68 FIGURE 30 HUMANIZED MOUSE AND RAT MODEL MARKET: PATENT ANALYSIS, 2014–2024 71 FIGURE 31 HUMANIZED MOUSE AND RAT MODEL MARKET: PORTER’S FIVE FORCES ANALYSIS 84 FIGURE 32 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS 85 FIGURE 33 KEY BUYING CRITERIA, BY END USER 86 FIGURE 34 AI USE CASES 88 FIGURE 35 HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023–2030 (THOUSAND UNITS) 91 FIGURE 36 HUMANIZED MOUSE AND RAT MODEL MARKET: NORTH AMERICA SNAPSHOT 133 FIGURE 37 HUMANIZED MOUSE AND RAT MODEL MARKET: ASIA PACIFIC SNAPSHOT 158 FIGURE 38 REVENUE ANALYSIS OF KEY PLAYERS IN HUMANIZED MOUSE AND RAT MODEL MARKET, 2020−2024 187 FIGURE 39 MARKET SHARE ANALYSIS OF HUMANIZED MOUSE AND RAT MODEL MARKET, 2024 188 FIGURE 40 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2024 190 FIGURE 41 COMPANY VALUATION AND FINANCIAL METRICS, 2024 190 FIGURE 42 HUMANIZED MOUSE AND RAT MODEL MARKET: BRAND/PRODUCT COMPARISON 191 FIGURE 43 HUMANIZED MOUSE AND RAT MODEL MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 193 FIGURE 44 HUMANIZED MOUSE AND RAT MODEL MARKET: COMPANY FOOTPRINT 194 FIGURE 45 HUMANIZED MOUSE AND RAT MODEL MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 199 FIGURE 46 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2024) 206 FIGURE 47 THE JACKSON LABORATORY: COMPANY SNAPSHOT (2024) 210 FIGURE 48 INOTIV: COMPANY SNAPSHOT (2024) 214 FIGURE 49 JSR CORPORATION: COMPANY SNAPSHOT (2024) 224 FIGURE 50 CHAMPIONS ONCOLOGY, INC.: COMPANY SNAPSHOT (2024) 228 FIGURE 51 HARBOUR BIOMED: COMPANY SNAPSHOT (2024) 235

同分類最新報告（醫療與生命科學）

查看醫療與生命科學全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們